Concurrent oral administration of either SILY or two doses of MLEO significantly decreased (p < 0.001) the TNF-α, IL-1β, IL-6, and NF-κB levels and significantly increased (p < 0.001) the IL-10 and adiponectin levels compared with the anti-TB drug mixture (INH/RIF/PZA) group. Here, IL1B is linked to tuberculosis.